CGEN · Compugen Ltd
United States · RS rating 39 · As of 2026-11-03
| Price | 2.01 USD |
|---|---|
| 1-day change | +1.5% |
| RS rating (overall / 1M / 3M / 12M) | 39 / 30 / 42 / 63 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 39 / 30 / 56 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +957.1% |
| Sales growth Q/Q | +3460.7% |
| Distance from 52-week high | +35.2% |
| Market cap (USD) | $276.1M |